Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors
Journal
Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531
Informations de publication
Date de publication:
28 04 2022
28 04 2022
Historique:
pubmed:
12
4
2022
medline:
30
4
2022
entrez:
11
4
2022
Statut:
ppublish
Résumé
Vitamin-D receptor (VDR) mRNA is overexpressed in neuroblastoma and carcinomas of lung, pancreas, and ovaries and predicts poor prognoses. VDR antagonists may be able to inhibit tumors that overexpress VDR. However, the current antagonists are arduous to synthesize and are only partial antagonists, limiting their use. Here, we show that the VDR antagonist MeTC7 (
Identifiants
pubmed: 35404047
doi: 10.1021/acs.jmedchem.1c01878
pmc: PMC9059124
doi:
Substances chimiques
Receptors, Calcitriol
0
Vitamins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6039-6055Subventions
Organisme : NIGMS NIH HHS
ID : R35 GM134864
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG071675
Pays : United States
Références
Mol Cell. 2000 Jan;5(1):173-9
pubmed: 10678179
Haematologica. 2013 Oct;98(10):1554-62
pubmed: 23716551
Histochem Cell Biol. 2020 Oct;154(4):421-429
pubmed: 32572587
J Med Chem. 2006 Jan 26;49(2):534-53
pubmed: 16420040
J Dermatolog Treat. 2009;20(4):208-12
pubmed: 19444692
Nat Rev Drug Discov. 2007 Oct;6(10):793-810
pubmed: 17906642
Mol Endocrinol. 2003 Nov;17(11):2320-8
pubmed: 12893883
J Biol Chem. 2005 Dec 9;280(49):40901-8
pubmed: 16207705
EMBO J. 1997 Jun 2;16(11):2985-95
pubmed: 9214616
Methods Mol Biol. 2011;776:59-68
pubmed: 21796520
Expert Opin Drug Discov. 2015 Jan;10(1):53-62
pubmed: 25345447
Crit Rev Oncol Hematol. 2010 Mar;73(3):192-201
pubmed: 19446468
Curr Drug Targets. 2002 Feb;3(1):85-94
pubmed: 11899952
Cancer Res. 2017 Feb 15;77(4):971-981
pubmed: 27923830
Clin Cancer Res. 2005 Jan 1;11(1):323-8
pubmed: 15671562
Cancer Res. 2009 Feb 1;69(3):967-75
pubmed: 19141646
Chem Biol Drug Des. 2006 Jan;67(1):83-4
pubmed: 16492153
Anticancer Res. 2021 Oct;41(10):4937-4946
pubmed: 34593441
Curr Vasc Pharmacol. 2014 Mar;12(2):294-9
pubmed: 23713873
Eur J Cancer. 2007 Jun;43(9):1467-75
pubmed: 17449239
Anticancer Res. 2006 Jul-Aug;26(4A):2557-66
pubmed: 16886664
J Biol Chem. 1999 Jun 4;274(23):16392-9
pubmed: 10347199
J Med Chem. 2020 Sep 10;63(17):9457-9463
pubmed: 32787090
J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):331-4
pubmed: 15225795
J Biol Chem. 2009 Dec 25;284(52):36292-36301
pubmed: 19801650
Am J Pathol. 2003 May;162(5):1603-10
pubmed: 12707044
Pharm Biol. 2015;53(10):1399-434
pubmed: 25856702
PLoS One. 2011 Apr 13;6(4):e18064
pubmed: 21533284
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Nat Rev Cancer. 2007 Sep;7(9):684-700
pubmed: 17721433
Pharmacol Rev. 2013 Mar 01;65(2):710-78
pubmed: 23457206
PLoS One. 2012;7(4):e34443
pubmed: 22509304
Cell. 2012 Mar 30;149(1):22-35
pubmed: 22464321
PLoS One. 2009 Sep 04;4(9):e6902
pubmed: 19730731
J Biol Chem. 2017 Dec 15;292(50):20657-20668
pubmed: 29061851
ACS Med Chem Lett. 2021 May 07;12(6):1024-1029
pubmed: 34141088
Nat Rev Cancer. 2003 Mar;3(3):203-16
pubmed: 12612655
Cold Spring Harb Perspect Med. 2013 Nov 01;3(11):
pubmed: 24186490
Cell. 2014 Sep 25;159(1):80-93
pubmed: 25259922
Front Oncol. 2021 Feb 08;10:623679
pubmed: 33628735
Steroids. 2001 Mar-May;66(3-5):227-37
pubmed: 11179730
Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18827-32
pubmed: 23112173
Reprod Sci. 2007 Jul;14(5):486-97
pubmed: 17913968
JNCI Cancer Spectr. 2018 Nov 16;2(3):pky047
pubmed: 31360864
J Biomol Screen. 2009 Jan;14(1):43-8
pubmed: 19171919
Genes Cancer. 2013 Nov;4(11-12):524-34
pubmed: 24386512
Cancer. 2006 May 15;106(10):2136-42
pubmed: 16598750
Curr Med Chem. 2013;20(33):4121-30
pubmed: 23895685
Gynecol Oncol. 2011 Nov;123(2):370-8
pubmed: 21803404
Pharmacol Ther. 2016 Aug;164:135-43
pubmed: 27113410
J Clin Endocrinol Metab. 2013 Oct;98(10):4023-9
pubmed: 23979953
Semin Cancer Biol. 2011 Oct;21(4):245-55
pubmed: 21958944